CN105237542A - Medicine composition for treating gynecological diseases - Google Patents
Medicine composition for treating gynecological diseases Download PDFInfo
- Publication number
- CN105237542A CN105237542A CN201510752206.4A CN201510752206A CN105237542A CN 105237542 A CN105237542 A CN 105237542A CN 201510752206 A CN201510752206 A CN 201510752206A CN 105237542 A CN105237542 A CN 105237542A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutical composition
- gynaecopathia
- treatment
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OCMKQNPWVXXNFG-STFUFVFFSA-N C[C@H](C1)C1c(cc1)cc2c1/N=C/C(/C(c1ccc(C)cc1)=O)=C1/NCCCCC1CCN2 Chemical compound C[C@H](C1)C1c(cc1)cc2c1/N=C/C(/C(c1ccc(C)cc1)=O)=C1/NCCCCC1CCN2 OCMKQNPWVXXNFG-STFUFVFFSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a medicine composition for treating gynecological diseases. The medicine composition comprises an effective quantity of compounds and carriers capable of being accepted in pharmacy. The structure of the compounds is shown in the specification. The compounds of the medicine composition have the remarkable effect on pathogenic bacteria causing the gynecological diseases and can be developed into the novel medicine composition effective in clinic.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of pharmaceutical composition for the treatment of gynaecopathia.
Background technology
Gynaecopathia is clinical common disease, and it is often because various pathogens causes, and the suppression therefore studied for pathogenic bacterium has great importance for treatment gynaecopathia.In the patient illness part secretory product of gynaecopathia, find that in the recent period bacteroides thetaiotaomicron ATCC29741 is also one of pathogenic bacterium wherein.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of gynaecopathia.
In order to realize object of the present invention, the invention provides a kind of compound for the treatment of gynaecopathia, this compound has having structure:
The present invention also provides a kind of pharmaceutical composition for the treatment of gynaecopathia, and described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
Preferably, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
Preferably, described thinner is lactose.
Preferably, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
The present invention also provides the purposes of compound in the medicine of preparation treatment gynaecopathia, and this compound has having structure:
Preferably, described infection is caused by bacteroides thetaiotaomicron ATCC29741.
The present invention also provides the purposes of compound in the medicine of preparation vitro inhibition bacteroides thetaiotaomicron ATCC29741, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to not eliminate the biologic activity of compound as herein described or the material of character, as carrier or thinner.This kind of material is applied to and individual does not cause undesirable biological action or not with harmful way and any component interaction comprised in its composition.
" pharmaceutically acceptable carrier " comprises any and all solvents as the term is employed herein, dispersion medium, coating material, tensio-active agent, antioxidant, sanitas (such as antiseptic-germicide, anti-mycotic agent), isotonic agent, absorption delay agent, salt, sanitas, drug stabilizing agent, tackiness agent, vehicle, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington'sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329).Except with except the inconsistent carrier of activeconstituents, consider to use any conventional carrier in treatment or pharmaceutical composition.
Compound of the present invention, for the pathogenic bacteria Be very effective causing gynaecopathia, can be developed to pharmaceutical composition effectively new clinically.
Embodiment
Below by way of the description of embodiment, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
The research of the purposes of experimental example the compounds of this invention in the medicine of preparation vitro inhibition bacteroides thetaiotaomicron ATCC29741
Bacteriostatic test
Use following compounds, adopt filter paper enzyme classical in this area to carry out bacteriostatic test, wherein:
The structural formula of target compound is:
For examination bacterial classification bacteroides thetaiotaomicron ATCC29741 purchased from Bei Nuo bio tech ltd, Shanghai.
Nutrient solution
Nutrient agar medium and nutrient broth, purchased from Chen Yu experimental installation company limited of BeiJing ZhongKe.
Test method
Bacteroides thetaiotaomicron ATCC29741 is inoculated in agar plate nutritive medium plane, evenly gathers during inoculation.
Take target compound 0.01 gram, add 12000 ml sterile waters, ultrasonic 30 minutes, then the filtering with microporous membrane of 0.22 μm, obtained solution.The aseptic circular filter paper sheet of tweezer, sprays above-mentioned solution to complete wetting, is attached in the agar plate nutritive medium plane of inoculated bacteria.Agar plate is placed in the incubator of 37 DEG C, incubation 4 hours.Measure the diameter of bacterial restrain.Measure and average for 3 times.
1.4 result
The mean diameter of the bacterial restrain of bacteroides thetaiotaomicron ATCC29741 is 14.12mm, and this shows that target compound has the effect of extremely strong vitro inhibition bacteroides thetaiotaomicron ATCC29741.
Claims (9)
1. treat a compound for gynaecopathia, it is characterized in that, this compound has having structure:
2. treat a pharmaceutical composition for gynaecopathia, it is characterized in that, described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
3. the pharmaceutical composition for the treatment of gynaecopathia according to claim 2, is characterized in that, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
4. the pharmaceutical composition for the treatment of gynaecopathia according to claim 3, is characterized in that, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
5. the pharmaceutical composition for the treatment of gynaecopathia according to claim 4, is characterized in that, described thinner is lactose.
6. the pharmaceutical composition for the treatment of gynaecopathia according to claim 3, is characterized in that, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
7. the purposes of compound in the medicine of preparation treatment gynaecopathia, it is characterized in that, this compound has having structure:
8. purposes according to claim 7, is characterized in that, described infection is caused by bacteroides thetaiotaomicron ATCC29741.
9. the purposes of compound in the medicine of preparation vitro inhibition bacteroides thetaiotaomicron ATCC29741, it is characterized in that, this compound has having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510752206.4A CN105237542A (en) | 2015-11-09 | 2015-11-09 | Medicine composition for treating gynecological diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510752206.4A CN105237542A (en) | 2015-11-09 | 2015-11-09 | Medicine composition for treating gynecological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105237542A true CN105237542A (en) | 2016-01-13 |
Family
ID=55035408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510752206.4A Pending CN105237542A (en) | 2015-11-09 | 2015-11-09 | Medicine composition for treating gynecological diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105237542A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105622619A (en) * | 2016-03-07 | 2016-06-01 | 郑海英 | Medicine composition for treating periodontitis |
-
2015
- 2015-11-09 CN CN201510752206.4A patent/CN105237542A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| 彭占荣: "《云南大学硕士研究生学位论文》", 31 December 2014 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105622619A (en) * | 2016-03-07 | 2016-06-01 | 郑海英 | Medicine composition for treating periodontitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083364B (en) | A kind of pharmaceutical composition for the treatment of the infantile respiratory tract infection that enterobacter cloacae causes | |
| CN105198903A (en) | Pharmaceutical composition for treating acute upper respiratory infection | |
| CN104086541B (en) | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection | |
| CN105237542A (en) | Medicine composition for treating gynecological diseases | |
| CN105085503A (en) | Medicine composition for treating respiratory tract infection | |
| CN105294535A (en) | Pharmaceutical composition used for treating pelvic inflammation | |
| CN105348183A (en) | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom | |
| CN105412076B (en) | Compound purposes in the medicine of preparation treatment infantile diarrhea | |
| CN105622619A (en) | Medicine composition for treating periodontitis | |
| CN105254477A (en) | Medicine composition for treatment of vaginitis | |
| CN105061331A (en) | Pharmaceutical composition for eliminating phlegm for children | |
| CN105218460A (en) | A kind of pharmaceutical composition for the treatment of enteritis | |
| CN105232542B (en) | A kind of pharmaceutical composition for the treatment of infantile pneumonia | |
| CN105232540A (en) | Drug combination for treating infection after burn | |
| CN105111185A (en) | Pharmaceutical composition for treating vaginitis of elder people | |
| CN105254700A (en) | Medicinal composition for treatment of infection after scald | |
| CN105348270A (en) | Medicine composition preventing dental body and dental pulp infection | |
| CN105232504A (en) | Medicine composition for treating infant recurrent respiratory tract infections | |
| CN105395538A (en) | Medicine composition treating acute upper respiratory infection | |
| CN105287478B (en) | A kind of pharmaceutical composition treating gastritis | |
| CN105232550B (en) | A kind of pharmaceutical composition treating chronic pelvic inflammatory disease | |
| CN105748477B (en) | A kind of medicine treating infantile enteritiss | |
| CN105503880A (en) | Medicine composition for treating respiratory diseases | |
| CN105330610A (en) | Medicine composition for treating gingivitis | |
| CN105125546A (en) | Medicine composition for treating postoperative wound infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160113 |